$75MSeries D, 2 June 2025
Funds two registrational Phase III trials of its bimatoprost drug-delivery implant.
- Amount
- $75M
- Stage
- Series D
- Announced
- 2 June 2025
- Lead
- Sands Capital
- Other investors
- Gilde Healthcare, NEA, RA Capital, Vensana Capital, Samsara BioCapital, Vertex Ventures HC
- Use of funds
- Funds two registrational Phase III trials of its bimatoprost drug-delivery implant.
- Checked
- Announced by the company
- Sources
- SpyGlass Pharma Raises $75 Million Series D Funding to - GlobeNewswire biospace.com
SpyGlass Pharma Raises $75 Million Series D Funding to globenewswire.com
SpyGlass Pharma Raises $75 Million Series D Funding to - GlobeNewswire news.crunchbase.com